Orexo Interim Report Q4 2022, incl. Full Year Report
Important steps forward in a challenging environment Q4 2022 highlights · Total net revenues of SEK 156.1 m (144.0) · EBITDA of SEK -53.1 m (-48.5), EBITDA excluding legal costs and costs for non-repeating clinical trials, SEK -0.1 m (-10.5) · Net earnings of SEK -91.8 m (-66.0) · US Pharma segment (ZUBSOLV® US) net revenues of SEK 142.6 m (133.6), in local currency USD 13.3 m (15.1), US Pharma EBIT of SEK 77.0 m (72.2) · Cash flow from operating activities of SEK -48.9 m (-80.6), cash and invested funds of SEK 351.9 m (504.1) a reduction of SEK 92,0 m from SEK 443.9 m